Women's constructions of the 'right time' to consider decisions about risk-reducing mastectomy and risk-reducing oophorectomy
- PMID: 20687957
- PMCID: PMC2927493
- DOI: 10.1186/1472-6874-10-24
Women's constructions of the 'right time' to consider decisions about risk-reducing mastectomy and risk-reducing oophorectomy
Abstract
Background: Women who are notified they carry a BRCA1/2 mutation are presented with surgical options to reduce their risk of breast and ovarian cancer, including risk-reducing mastectomy (RRM) and risk-reducing oophorectomy (RRO). Growing evidence suggests that a sub-group of women do not make decisions about RRM and RRO immediately following genetic testing, but rather, consider these decisions years later. Women's perspectives on the timing of these decisions are not well understood. Accordingly, the purpose of this research was to describe how women construct the 'right time' to consider decisions about RRM and RRO.
Methods: In-depth interviews were conducted with 22 BRCA1/2 carrier women and analyzed using qualitative, constant comparative methods.
Results: The time that lapsed between receipt of genetic test results and receipt of RRM or RRO ranged from three months to nine years. The findings highlighted the importance of considering decisions about RRM and RRO one at a time. The women constructed the 'right time' to consider these decisions to be when: (1) decisions fit into their lives, (2) they had enough time to think about decisions, (3) they were ready emotionally to deal with the decisions and the consequences, (4) all the issues and conflicts were sorted out, (5) there were better options available, and (6) the health care system was ready for them.
Conclusions: These findings offer novel insights relevant to health care professionals who provide decision support to women considering RRM and RRO.
Similar articles
-
Intentions for risk-reducing surgery among high-risk women referred for BRCA1/BRCA2 genetic counseling.Psychooncology. 2015 Jan;24(1):33-9. doi: 10.1002/pon.3560. Epub 2014 May 17. Psychooncology. 2015. PMID: 24839250 Free PMC article.
-
BRCA1/2 test results impact risk management attitudes, intentions, and uptake.Breast Cancer Res Treat. 2010 Dec;124(3):755-64. doi: 10.1007/s10549-010-0881-4. Epub 2010 Apr 10. Breast Cancer Res Treat. 2010. PMID: 20383578 Free PMC article.
-
Long-term outcomes of BRCA1/BRCA2 testing: risk reduction and surveillance.Cancer. 2012 Jan 15;118(2):510-7. doi: 10.1002/cncr.26294. Epub 2011 Jun 29. Cancer. 2012. PMID: 21717445 Free PMC article.
-
Women's decision making about risk-reducing strategies in the context of hereditary breast and ovarian cancer: a systematic review.J Genet Couns. 2009 Dec;18(6):578-97. doi: 10.1007/s10897-009-9245-9. Epub 2009 Oct 3. J Genet Couns. 2009. PMID: 19802692
-
Prophylactic mastectomy: why and when?J Br Menopause Soc. 2003 Dec;9(4):151-5. doi: 10.1258/136218003323010584. J Br Menopause Soc. 2003. PMID: 15107257 Review.
Cited by
-
Psychological factors and the uptake of preventative measures in BRCA1/2 pathogenic variant carriers: results of a prospective cohort study.Hered Cancer Clin Pract. 2022 Dec 19;20(1):38. doi: 10.1186/s13053-022-00244-y. Hered Cancer Clin Pract. 2022. PMID: 36536421 Free PMC article.
-
Coping Self-Efficacy and Its Relationship with Psychological Morbidity after Genetic Test Result Disclosure: Results from Cancer-Unaffected BRCA1/2 Mutation Carriers.Int J Environ Res Public Health. 2023 Jan 17;20(3):1684. doi: 10.3390/ijerph20031684. Int J Environ Res Public Health. 2023. PMID: 36767056 Free PMC article. Clinical Trial.
-
Timing of risk reducing mastectomy in breast cancer patients carrying a BRCA1/2 mutation: retrospective data from the Dutch HEBON study.Fam Cancer. 2015 Sep;14(3):355-63. doi: 10.1007/s10689-015-9788-x. Fam Cancer. 2015. PMID: 25700605 Free PMC article.
-
Population genomic screening: Ethical considerations to guide age at implementation.Front Genet. 2022 Oct 4;13:899648. doi: 10.3389/fgene.2022.899648. eCollection 2022. Front Genet. 2022. PMID: 36267415 Free PMC article. Review.
-
Racial differences in prevention decision making among U.S. women at high risk of breast cancer: A qualitative study.PLoS One. 2023 Mar 1;18(3):e0278742. doi: 10.1371/journal.pone.0278742. eCollection 2023. PLoS One. 2023. PMID: 36857397 Free PMC article.
References
-
- Antoniou A, Pharoah PD, Narod S, Risch HA, Eyfjord JE, Hopper JL, Loman N, Olsson H, Johannsson O, Borg A, Pasini B, Radice P, Manoukian S, Eccles DM, Tang N, Olah E, Anton-Culver H, Warner E, Lubinski J, Gronwald J, Gorski B, Tulinius H, Thorlacius S, Eerola H, Nevanlinna H, Syrjakoski K, Kallioniemi OP, Thompson D, Evans C, Peto J, Lalloo F, Evans DG, Easton DF. Average risks of breast and ovarian cancer associated with BRCA1 or BRCA2 mutations detected in case series unselected for family history: A combined analysis of 22 studies. Am J of Hum Genet. 2003;72:1117–1130. doi: 10.1086/375033. - DOI - PMC - PubMed
-
- Evans DG, Shenton A, Woodward E, Lalloo F, Howell A, Maher ER. Penetrance estimates for BRCA1 and BRCA2 based on genetic testing in a clinical cancer genetics service setting: Risks of breast/ovarian cancer quoted should reflect the cancer burden in the family. BMC Cancer. 2008;8:155. doi: 10.1186/1471-2407-8-155. - DOI - PMC - PubMed
-
- Ford D, Easton DF, Stratton M, Narod S, Goldgar D, Devilee P, Bishop DT, Weber B, Lenoir G, Chang-Claude J, Sobol H, Teare MD, Struewing J, Arason A, Scherneck S, Peto J, Rebbeck TR, Tonin P, Neuhausen S, Barkardottir S, Eyfjord J, Lynch H, Ponder BA, Gayther SA, Zelada-Hedman M. Genetic heterogeneity and penetrance analysis of the BRCA1 and BRCA2 genes in breast cancer families. The breast cancer linkage consortium. Am J Hum Genet. 1998;62:676–689. doi: 10.1086/301749. - DOI - PMC - PubMed
Publication types
MeSH terms
Grants and funding
LinkOut - more resources
Full Text Sources
Medical
Miscellaneous